Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis Li 2025

No abstract


In summary, our study shows robust expansion of CAR T-cells in vivo, complete elimination of CD19 B-cells, clearance of RA-related autoantibodies, and high-level sustained clinical responses in RA patients, supporting a very recent observation in a patient with RA and coexisting myasthenia gravis.15 However, the patient reported by Haghikia et al.15 was not a typical RA patient refractory to multiple RA therapeutics. Therefore, our data show the feasibility of a fourth-generation CAR T-cell treatment approach in treatment-resistant RA with amelioration of inflammation and reduction of autoantibodies. This is the first time that a fourth-generation CAR has been used for the treatment of autoimmune disease and the rationale for combining cytokine inhibition and B-cell depletion in one approach bears huge opportunities to better control diseases like RA in the future.

https://www.nature.com/articles/s41422-024-01068-2